Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06345404
Status:
RECRUITING
Last Update Posted:
2024-04-10
First Post:
2024-03-12
Brief Title:
Safety Tolerability and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Sponsor:
Corvus Pharmaceuticals Inc
Organization:
Corvus Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 1 Randomized Blinded Placebo-controlled Dose Escalation Study to Investigate the Safety Tolerability and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic Dermatitis
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Safety tolerability and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Detailed Description:
A Phase 1 Randomized Blinded Placebo-controlled Dose Escalation Study to Investigate the Safety Tolerability and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants with Moderate to Severe Atopic Dermatitis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None